Bispecific Antibody Assembly via Interface Residue Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for co-administering multiple antibody therapies face challenges in stability, bioavailability, and manufacturing costs, particularly in designing suitable pharmaceutical formulations for co-formulations of antibody agents, which can lead to patient discomfort and increased regulatory and manufacturing expenses.
Innovation Solution
The method involves co-expressing nucleic acids encoding specific heavy and light chain variable and constant domains in a host cell to produce bispecific antibodies with improved specificity and stability, allowing for the combination of binding specificities and activities of two distinct therapeutic antibodies into a single compound, utilizing designed residues in the interface domains to enhance assembly and binding properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If co-formulation of multiple antibody agents is used, then fewer injections are required, but formulation stability and bioavailability become difficult to maintain
Solution Approach 1:
The patent merges multiple antibody binding specificities into a single bispecific antibody molecule, combining the functions of two separate antibodies into one therapeutic agent that can be administered as a single formulation, thereby reducing the number of injections while maintaining stability
Solution Approach 2:
The patent creates a composite antibody structure with two different Fab regions derived from two distinct antibodies, forming a single molecule that integrates the binding capabilities of both parent antibodies while maintaining proper IgG architecture and stability
2Reliability
If separate antibody agents are administered, then formulation stability is easier to maintain, but manufacturing and regulatory costs increase
Solution Approach 1:
The patent combines multiple therapeutic functions into a single bispecific antibody product, reducing the need to manufacture and regulate multiple separate antibody agents, thereby lowering overall manufacturing and regulatory costs while maintaining formulation stability
3Ease of manufacture
If multiple injections are used, then manufacturing cost is reduced, but patient compliance decreases due to inconvenience
Solution Approach 1:
The patent merges multiple antibody therapies into a single bispecific antibody that can be administered as one injection, improving patient compliance and convenience while maintaining cost-effectiveness through streamlined manufacturing and regulatory processes
4Productivity
If co-expression of multiple HC-LC pairs is used, then bisspecific antibody production is achieved, but mis-matched byproduct generation increases
Solution Approach 1:
The patent introduces asymmetric modifications at the HC-HC interface, creating distinct structural features that enable specific pairing of heavy chains and prevent mis-matched byproducts, thereby improving assembly specificity while maintaining productivity
Solution Approach 2:
The patent applies localized modifications specifically at the HC-HC interface regions, altering only the relevant interface properties to enhance pairing specificity without affecting the overall structure or function of the antibody molecule
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain- light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1 /CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.